1541198-99-5

Upstream product

• 1096698-34-8 2-(3,5-dibromophenyl)-2-methylpropanenitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 1541198-98-4 2-(3-bromo-5-(1,3-dioxolan-2-yl)phenyl)-2-methylpropanenitrile 

Downstream Products

• 1541199-02-3 (S)-3-amino-3-(3-bromo-5-(2-cyanopropan-2-yl)phenyl)propanoicacid 
• 1541199-03-4 C₁₅H₁₉BrN₂O₂ 
• 1541198-95-1 (S)-ethyl 3-amino-3-(3-bromo-5-(2-cyanopropan-2-yl)phenyl)propanoate hydrochloride 
• 1541199-04-5 (3S)-ethyl 3-(3-bromo-5-(2-cyanopropan-2-yl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate 
• 1541197-05-0 (3S)-3-(3-bromo-5-(2-cyanopropan-2-yl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid 
• 1541199-00-1 ethyl 3-amino-3-(3-bromo-5-(2-cyanopropan-2-yl)phenyl)propanoate 
• 1541199-01-2 (E)-ethyl 3-(3-bromo-5-(2-cyanopropan-2-yl)phenyl)acrylate 

Relevant academic research and scientific papers

KINASE INHIBITORS

A DDR1 inhibitor compound can have a structure of Formula A, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center, ring A is a ring s

BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.